miransertib mesylate

Miransertib mesylate is a selective AKT inhibitor that binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K AKT signaling pathway. This may result in reduction in tumor cell proliferation and the induction of tumor cell apoptosis.

MeTC7 是一种维生素 D 受体 (VDR) 拮抗剂，具有抗肿瘤活性，抑制 PD-L1，可在体内抑制异种移植物和转基因肿瘤的生长。